---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032097"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:19:25.967053+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net

## Summary
- Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.
- Adjusted EBITDA $22.1M (+26% YoY); non-GAAP net income $4.2M ($0.08 diluted EPS) vs $2.5M ($0.06) in prior year.
- Full-year 2026 revenue guidance lowered to $480-496M (prev $486-504M); adjusted EBITDA guidance lowered to $100-107M (prev $105-110M).
- Exercised option to acquire Endospan; base price $175M, net ~$135M after offsetting loans; contingent consideration up to $200M; closing expected Q2 2026.
- FDA approved NEXUS Aortic Arch System on April 2, 2026, triggering option exercise; commercial launch planned Jan 1, 2027.

## SEC filing metadata
- accession: 0001628280-26-032097
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/0001628280-26-032097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/aort-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032097
- JSON: https://secwatch.observer/filing/0001628280-26-032097.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032097.txt

## Source-grounded claims
- claim_id: 0d3716b56472032ea615d883bc4a202806f2cf9d
  claim: ARTIVION, INC. reported first quarter ended March 31, 2026 results: revenue $116.3 million, net income $1.4 million, EPS $0.03 per fully diluted share. Guidance lowered.
  evidence_excerpt: Total revenues for the first quarter of 2026 were $116.3 million, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis, both compared to the first quarter of 2025. Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted common share, compared to net loss of $(0.5) million, or $(0.01) per fully diluted common share for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/0001628280-26-032097-index.htm
- claim_id: a4357bd0d17726407bc4c20ebf0a8951144edd62
  claim: ARTIVION, INC. entered into Securities Purchase Option Agreement with Endospan Ltd., the securityholders of Endospan listed on Schedule 1, and Shareholder Representative Services LLC valued at base purchase price of $175.0 million (effective 2019-09-11).
  evidence_excerpt: on September 11, 2019, Artivion, Endospan, the securityholders of Endospan listed on Schedule 1 thereto (together with any additional securityholder that becomes a party by joinder, the “Securityholders”), and Shareholder Representative Services LLC, as the Securityholder representative, entered into a Securities Purchase Option Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/0001628280-26-032097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.